Share Capital (Tables)

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Schedule of the effect of share-based compensation on the statements of operations

	Year ended		Year ended
	December 31,		December 31,
	2022		2021
	USD thousands		USD thousands
Research and development		448		137
General and administrative		2,763		1,882
Total share-based compensation expenses		3,211		2,019

Schedule of number and weighted average exercise prices of option

	Weighted average exercise price		Number of options			Weighted average remaining contractual life (in years)		Weighted average exercise price		Number of options			Weighted average remaining contractual life (in years)
	2022		2022			2022		2021		2021			2021
Outstanding at January 1		0.38		27,003,260			8.12		0.07		10,455,580			7.8
Acquired in Merger		-		-			-				609,535			-
Exercised		0.07		(1,970,000	)		-		0.08		(134,220	)		-
Forfeited		0.32		(1,240,120	)		-		1.25		(1,712,275	)		-
Granted		0.16		11,398,400			7.8		0.62		17,784,640			9.79
Outstanding at December 31		0.33		35,191,540			7.42		0.38		27,003,260			8.12

Schedule of assumptions used to calculate the fair value of the options

	2022 grants
Weighted average share price (in U.S. dollar)(a)		0.16
Exercise price (in U.S. dollar)		0.10-0.257
Expected life of options (in years)(b)		5.51-6.28
Expected volatility(c)		83.69%-84.31%
Risk-free interest rate(d)		1.75%-4.14%
Dividend yield		0%